Interleukin-2 (IL-2) Mutein Therapies Market Report 2026

Interleukin-2 (IL-2) Mutein Therapies Market Overview

• Interleukin-2 (IL-2) Mutein Therapies market size has reached to $0.73 billion in 2025 • Expected to grow to $1.43 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: The Increasing Demand For Targeted Immunotherapies The Growth Of The Market Due To Advancements In Immune-Based Cancer Treatments • Market Trend: Focus On Advancing Cytokine-based Immunotherapy Through Selective Regulatory T-cell Activation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Interleukin-2 (IL-2) Mutein Therapies Market?

Interleukin-2 (IL-2) mutein therapies refer to engineered variants of the natural IL-2 cytokine that have been structurally modified to selectively alter receptor binding and immune cell activation. These therapies are designed to enhance therapeutic efficacy and safety by preferentially stimulating specific immune cell populations, such as regulatory T cells or effector T cells, while reducing toxicity. The main product types of interleukin-2 (IL-2) mutein therapies include monotherapy and combination therapy. Monotherapy refers to treatments where IL-2 muteins are administered alone to modulate the immune system for therapeutic purposes. These therapies are administered via routes including intravenous, subcutaneous, and other routes of administration. They are applied across areas including cancer, autoimmune diseases, infectious diseases, and other applications, and are used by end users including hospitals, specialty clinics, research institutes, and other end users.

What Is The Interleukin-2 (IL-2) Mutein Therapies Market Growth Forecast?

The interleukin-2 (il-2) mutein therapies market size is expected to see rapid growth in the next few years. It will grow to $1.43 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to expansion of personalized immunotherapy approaches, increasing clinical trial activity for next-generation cytokines, rising demand for safer immune modulators, growing regulatory support for innovative biologics, increasing partnerships between biotech and pharma companies. Major trends in the forecast period include increasing development of receptor-biased il-2 muteins, rising focus on reduced cytokine toxicity profiles, growing use of combination immunotherapy regimens, expansion of precision immune modulation approaches, enhanced clinical pipeline activity for autoimmune and oncology indications.

Global Interleukin-2 (IL-2) Mutein Therapies Market Segmentation

1) By Product Type: Monotherapy; Combination Therapy 2) By Route Of Administration: Intravenous; Subcutaneous; Other Route Of Administrations 3) By Application: Cancer; Autoimmune Diseases; Infectious Diseases; Other Applications 4) By End User: Hospitals; Specialty Clinics; Research Institutes; Other End Users Subsegments: 1) By Monotherapy: Single Agent Interleukin Two Mutein Therapy; Standalone Cytokine Based Immunotherapy; Targeted Immune Modulation Therapy 2) By Combination Therapy: Interleukin Two Mutein With Immune Checkpoint Inhibitors; Interleukin Two Mutein With Chemotherapy; Interleukin Two Mutein With Targeted Biologic Therapies; Interleukin Two Mutein With Cell Based Therapies

What Is The Driver Of The Interleukin-2 (IL-2) Mutein Therapies Market?

The increasing demand for targeted immunotherapies is expected to propel the growth of the interleukin-2 (IL-2) mutein therapies market. Targeted immunotherapies are treatments designed to modulate the immune system to selectively attack cancer cells while minimizing damage to healthy tissues. Demand for these therapies is rising as healthcare providers and researchers seek safer, more effective alternatives to conventional chemotherapy and radiation therapy, which are often associated with significant toxicity and limited specificity. IL-2 mutein therapies support the advancement of targeted immunotherapies by utilizing engineered variants of interleukin-2 that selectively stimulate immune effector cells involved in anti-tumor responses while reducing activation of pathways associated with systemic toxicity. For instance, in April 2025, according to the Cancer Research Institute, a US-based non-profit organization, FDA approvals included 17 new targeted immunotherapy agents in 2024, expanding options for targeted immune-based cancer treatment and increasing the pool of patients who can benefit from such therapies. Therefore, the increasing demand for targeted immunotherapies is driving the growth of the interleukin-2 (IL-2) mutein therapies industry.

Key Players In The Global Interleukin-2 (IL-2) Mutein Therapies Market

Major companies operating in the interleukin-2 (il-2) mutein therapies market are Merck & Co. Inc., Sanofi S.A., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Lonza Group AG, Alkermes plc, BioNTech SE, Xencor Inc., Innovent Biologics Inc., Ascendis Pharma A/S, ShanghAI Junshi Biosciences Co. Ltd., Mural Oncology Inc., ProBioGen AG, Werewolf Therapeutics Ltd., Philogen S.p.A., Cue Biopharma Inc., Medicenna Therapeutics Corp., Bright Peak Therapeutics Inc., Iovance Biotherapeutics Inc.

Global Interleukin-2 (IL-2) Mutein Therapies Market Trends and Insights

Major companies operating in the interleukin-2 (IL-2) mutein therapies market are increasingly focusing on technological advancements in cytokine-based immunotherapy, such as selective regulatory T-cell (Treg) activation through engineered IL-2 muteins. Selective regulatory T-cell activation via engineered IL-2 muteins involves the use of genetically modified IL-2 proteins designed to preferentially stimulate Tregs while limiting activation of effector immune cells. For instance, in December 2023, Almirall S.A., a Spain-based pharmaceutical company, initiated the first Phase I clinical study of its engineered IL-2 mutein fusion protein, ALM223, to evaluate safety, pharmacokinetics, immunogenicity, and pharmacodynamics in autoimmune diseases. The candidate features selective Treg activation, a modified Fc fusion to improve molecular stability, and an engineered cytokine backbone to optimize immune modulation. While these technological advances highlight the promise of IL-2 muteins in achieving targeted immunomodulation and broader autoimmune applicability, their clinical efficacy and long-term safety profiles remain to be established through ongoing and future trials.

What Are Latest Mergers And Acquisitions In The Interleukin-2 (IL-2) Mutein Therapies Market?

In January 2025, Asher Biotherapeutics Inc., a US-based biotechnology company developing and owning IL-2 mutein therapeutics, entered into a partnership with Amgen Inc. to evaluate etakafusp alfa in combination with IMDELLTRA in a Phase 1b clinical trial for extensive-stage small cell lung cancer (ES-SCLC). Through this partnership, the companies aim to advance the clinical development of etakafusp alfa by assessing its potential to enhance T cell–mediated anti-tumor activity when used alongside IMDELLTRA in patients with ES-SCLC. Amgen Inc. is a US-based biotechnology company that develops and commercializes innovative therapies across oncology and other therapeutic areas.

Regional Insights

North America was the largest region in the interleukin 2 (IL-2) mutein therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Interleukin-2 (IL-2) Mutein Therapies Market?

The interleukin-2 (IL-2) mutein therapies market consists of sales of efavaleukin alfa, rezpegaldesleukin, bempegaldesleukin, nemvaleukin alfa.Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Interleukin-2 (IL-2) Mutein Therapies Market Report 2026?

The interleukin-2 (il-2) mutein therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin-2 (il-2) mutein therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.